Evolving Standard Of Care May Be To Blame For Phase III Failure Of Ulimorelin, Tranzyme Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
An evolution in the methods hospitals use to speed gastrointestinal recovery after abdominal surgery may have undercut the Phase III efficacy results for the intravenous ghrelin agonist, which was shown to be no better than placebo in the first of two pivotal trials to report.
You may also be interested in...
Tranzyme Finds Perfect Fit In European Partner For Gastric Motility Drug
Tranzyme and Norgine will co-develop and co-commercialize ulimorelin, which should begin Phase III trials later this year.
FDA’s Strongest REMS To Date: Entereg Approved With Controlled-Distribution
Adolor and marketing partner GlaxoSmithKline's post-operative constipation therapy Entereg is the first drug to clear FDA with its highest level of Risk Evaluation and Mitigation Strategy - a required controlled distribution program. Entereg is at least the fifth new drug, and the second new molecular entity, to be approved with a REMS since the new authority granted by the FDA Amendments Act went into effect March 25
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.